Article: PI3K Isoform Immunotherapy for Solid Tumours.
Current topics in microbiology and immunology
2022 Volume 436, Page(s) 369–392
Abstract: Improving the anti-tumour T cell response as a consequence of immunotherapy can result in eradication of tumour burden, however, the majority of patients fail with current treatment regimens and so novel immunotherapies with greater efficacy and improved ...
Abstract | Improving the anti-tumour T cell response as a consequence of immunotherapy can result in eradication of tumour burden, however, the majority of patients fail with current treatment regimens and so novel immunotherapies with greater efficacy and improved tolerability are needed. The phosphoinositide-3-kinase (PI3K) family members that are directly involved in cell signalling comprise PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, with the latter two isoforms expressed primarily by leukocytes. The survival and optimal function of regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSCs) is dependent on PI3Kδ, whereas tumour-associated macrophages (TAMs), use PI3Kγ. Blocking these signalling isoforms can boost development of effective anti-cancer immune responses and result in control of tumour burden. The dependence on different PI3K isoforms in immune cells makes targeting this pathway an attractive approach for tumour immunotherapy. Herein, we discuss how inhibiting specific PI3K isoforms in pro-tumoural Tregs, MDSCS and TAMs can unleash a powerful anti-tumour immune response, driven by CD8 |
---|---|
MeSH term(s) | CD8-Positive T-Lymphocytes ; Humans ; Immune Checkpoint Inhibitors ; Immunotherapy ; Neoplasms/drug therapy ; Phosphatidylinositol 3-Kinase ; Phosphatidylinositol 3-Kinases/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Phosphatidylinositols/therapeutic use ; Phosphoinositide-3 Kinase Inhibitors ; Protein Isoforms/genetics ; Protein Isoforms/therapeutic use |
Chemical Substances | Immune Checkpoint Inhibitors ; Phosphatidylinositols ; Phosphoinositide-3 Kinase Inhibitors ; Protein Isoforms ; Phosphatidylinositol 3-Kinase (EC 2.7.1.137) |
Language | English |
Publishing date | 2022-09-29 |
Publishing country | Germany |
Document type | Journal Article ; Review |
ZDB-ID | 210099-X |
ISSN | 0070-217X |
ISSN | 0070-217X |
DOI | 10.1007/978-3-031-06566-8_16 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Ud II Zs.24: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.